Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL
Olga Kourti(AHEPA University Hospital), George Giannakoulas(AHEPA University Hospital), Haralambos Karvounis(Aristotle University of Thessaloniki), Orestis Konstantas(AHEPA University Hospital), Spyridon Graidis(AHEPA University Hospital), Stefanos Zafeiropoulos(AHEPA University Hospital), Ioannis T. Farmakis(Johannes Gutenberg University Mainz), Konstantina Spyridaki(AHEPA University Hospital), Georgios Psarakis(AHEPA University Hospital), Amalia Baroutidou(Aristotle University of Thessaloniki), Anastasia Daniilidou(AHEPA University Hospital), Aikaterini Vasiliki Touriki(AHEPA University Hospital), Christos Tsolakidis(AHEPA University Hospital), Eleni Vrana(Aristotle University of Thessaloniki), Thomas Psathas(AHEPA University Hospital)
Cited by 7
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
COVID-19 in Adults With Congenital Heart Disease
|Journal of the American College of Cardiology|2021|76
Prognostic significance of diabetes mellitus in patients with atrial fibrillation
|Cardiovascular Diabetology|2021|48
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
|Respiratory Medicine|2020|35
Haemoptysis in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: Insights on Pathophysiology, Diagnosis and Management
|Journal of Clinical Medicine|2022|22